[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 1990

Intra-arterial Floxuridine vs Systemic Fluorouracil for Hepatic Metastases From Colorectal Cancer: A Randomized Trial

Author Affiliations

From the Department of Surgery (Drs Martin and Nagorney), Division of Medical Oncology (Drs O'Connell and Rubin), and the Cancer Center Statistics Unit (Dr Wieand), Mayo Clinic, Rochester, Minn, and the Duluth (Minn) Clinic Community Clinic Oncology Program (Dr Krook); Creighton University, Omaha, Neb (Drs Fitzgibbons and Mailliard); and Sioux Community Cancer Consortium Community Clinic Oncology Program, Sioux Falls, SD (Dr Tschetter).

Arch Surg. 1990;125(8):1022-1027. doi:10.1001/archsurg.1990.01410200086013

• Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection. Eligible patients were randomized to hepatic arterial chemotherapy with an implanted infusion pump or systemic chemotherapy. No crossover between treatment arms was permitted, and patients were followed up to progression and death. Objective tumor response was observed in 48% of patients receiving intra-arterial floxuridine and in 21% of patients receiving intravenous fluorouracil. Time to hepatic progression was significantly longer in the group given intra-arterial therapy: 15.7 vs 6.0 months. However, time to overall progression (6.0 vs 5.0 months) and survival (12.6 vs 10.5 months) were not statistically different. Based on these data, we cannot recommend treatment with intra-arterial floxuridine as given in this study for metastatic colorectal cancer to the liver.

(Arch Surg. 1990;125:1022-1027)